{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:21:49Z","timestamp":1779164509238,"version":"3.51.4"},"reference-count":24,"publisher":"BMJ","issue":"Suppl 1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department for Digital, Culture Media & Sport \/ Ovarian Cancer Action","award":["A2025"],"award-info":[{"award-number":["A2025"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Qual"],"accepted":{"date-parts":[[2024,7,3]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Survival from ovarian cancer in the UK is poor compared with international comparators. The Ovarian Cancer Audit Feasibility Pilot demonstrated variation in 1-year and 5-year survival across the UK as well as significant variation in treatment rates. In 2020, IMPROVE-UK was established as the first major programme to address inequalities in ovarian cancer management and survival across the UK, to develop a legacy of best practice sharing across the country and to establish and evaluate quality improvement projects that could drive care at scale.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Following a competitive process, seven quality improvement projects were funded to address inequalities in care and identify strategies to improve and equalise survival rates for all women with ovarian cancer in the UK, to address health inequalities from geography, age or ethnicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Projects addressed the secondary care diagnostic pathway, genomic testing, prehabilitation and improving treatment-related decision-making, particularly decisions for surgery. All seven projects at least partial achieved their aims with numerous areas across all projects identified where processes could be refined and incorporated into standard care to improve outcomes of women diagnosed with ovarian cancer. Dissemination of information regarding best practice has been undertaken.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IMPROVE-UK was the first programme of its kind addressing significant inequalities of care in women with ovarian cancer. We demonstrate systematic quality improvement projects in ovarian cancer targeting various aspects of the treatment journey. Scaling up the results of the improve UK pilots is likely to improve survival in the UK and potentially internationally.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjoq-2024-002902","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:06:00Z","timestamp":1740485160000},"page":"e002902","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Key clinical findings from the IMPROVE-UK quality improvement projects: an overview"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0952-6810","authenticated-orcid":false,"given":"Andrew James","family":"Phillips","sequence":"first","affiliation":[{"name":"University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Bowen","sequence":"additional","affiliation":[{"name":"Dyson Cancer Centre, Royal United Hospital Bath NHS Trust, Bath, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5789-2773","authenticated-orcid":false,"given":"Mary","family":"Wells","sequence":"additional","affiliation":[{"name":"Nursing Directorate, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"McNeish","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudha","family":"Sundar","sequence":"additional","affiliation":[{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"},{"name":"Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"2025083111012165000_14.Suppl_1.e002902.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.389"},{"key":"2025083111012165000_14.Suppl_1.e002902.2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24149"},{"key":"2025083111012165000_14.Suppl_1.e002902.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3106"},{"key":"2025083111012165000_14.Suppl_1.e002902.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2017.04.016"},{"key":"2025083111012165000_14.Suppl_1.e002902.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011"},{"key":"2025083111012165000_14.Suppl_1.e002902.6","unstructured":"NICE . Maximal Cytoreductive surgery for advanced ovarian cancer. 2023."},{"key":"2025083111012165000_14.Suppl_1.e002902.7","unstructured":"NICE . Ovarian cancer: recognition and initial management. 2023."},{"key":"2025083111012165000_14.Suppl_1.e002902.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30456-5"},{"key":"2025083111012165000_14.Suppl_1.e002902.9","unstructured":"National Disease Registration Service ,. Short-term mortality in ovarian, Fallopian tube and primary peritoneal Carcinomas across England. 2021."},{"key":"2025083111012165000_14.Suppl_1.e002902.10","unstructured":"Public Health England ,. Geographic variation in ovarian, Fallopian tube and primary peritoneal cancer treatment in England. 2020."},{"key":"2025083111012165000_14.Suppl_1.e002902.11","unstructured":"Public Health England ,. Disease profile in England: incidence, mortality, stage and survival for ovary, Fallopian tube and primary peritoneal Carcinomas. 2020."},{"key":"2025083111012165000_14.Suppl_1.e002902.12","unstructured":"HICO . Placeholder."},{"key":"2025083111012165000_14.Suppl_1.e002902.13","unstructured":"NIOCPP . Placeholder."},{"key":"2025083111012165000_14.Suppl_1.e002902.14","unstructured":"DEMO . Placeholder."},{"key":"2025083111012165000_14.Suppl_1.e002902.15","unstructured":"IMPRESS . Placeholder."},{"key":"2025083111012165000_14.Suppl_1.e002902.16","unstructured":"AWOCPP . Placeholder."},{"key":"2025083111012165000_14.Suppl_1.e002902.17","unstructured":"AOCP . Placeholder."},{"key":"2025083111012165000_14.Suppl_1.e002902.18","unstructured":"SCOF . Placeholder."},{"key":"2025083111012165000_14.Suppl_1.e002902.19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ejso.2023.03.210","article-title":"MDT practice determines treatment pathway for patients with advanced ovarian cancer: a multi-centre observational study","volume":"49","author":"Khassan","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"2025083111012165000_14.Suppl_1.e002902.20","unstructured":"National Cancer Audit Collaborating Centre . National ovarian cancer audit. 2024. Available: https:\/\/natcanorgukprd.wpengine.com\/resources\/?audience%5B%5D=ovarian"},{"key":"2025083111012165000_14.Suppl_1.e002902.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2022-000012","article-title":"COVID-19 and cancer in the UK: which will prove to be the lesser of two evils","volume":"2","author":"Aggarwal","year":"2023","journal-title":"bmjonc"},{"key":"2025083111012165000_14.Suppl_1.e002902.22","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/1471-0528.17041","article-title":"Quality of life from Cytoreductive surgery in advanced ovarian cancer: investigating the association between disease burden and surgical complexity in the International, prospective, SOCQER-2 cohort study","volume":"129","author":"Sundar","year":"2022","journal-title":"BJOG"},{"key":"2025083111012165000_14.Suppl_1.e002902.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-022-01882-z","article-title":"Considerations for Multimodal Prehabilitation in women with gynaecological cancers: a scoping review using realist principles","volume":"22","author":"Saggu","year":"2022","journal-title":"BMC Womens Health"},{"key":"2025083111012165000_14.Suppl_1.e002902.24","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.12968\/bjon.2020.29.10.S6","article-title":"Changing practice: moving to a specialist nurse-led service for BRCA gene testing","volume":"29","author":"Scott","year":"2020","journal-title":"Br J Nurs"}],"container-title":["BMJ Open Quality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjoq-2024-002902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T18:01:31Z","timestamp":1756663291000},"score":1,"resource":{"primary":{"URL":"https:\/\/qir.bmj.com\/lookup\/doi\/10.1136\/bmjoq-2024-002902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":24,"journal-issue":{"issue":"Suppl 1","published-online":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjoq-2024-002902"],"URL":"https:\/\/doi.org\/10.1136\/bmjoq-2024-002902","relation":{},"ISSN":["2399-6641"],"issn-type":[{"value":"2399-6641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}